327 related articles for article (PubMed ID: 18952300)
1. Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA.
Huisman W; Schrauwen EJ; Tijhaar E; Süzer Y; Pas SD; van Amerongen G; Sutter G; Rimmelzwaan GF; Osterhaus AD
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):332-8. PubMed ID: 18952300
[TBL] [Abstract][Full Text] [Related]
2. Should accessory proteins be structural components of lentiviral vaccines? Lessons learned from the accessory ORF-A protein of FIV.
Pistello M
Vet Immunol Immunopathol; 2008 May; 123(1-2):144-9. PubMed ID: 18304653
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats.
Huisman W; Schrauwen EJ; Pas SD; van Amerongen G; Rimmelzwaan GF; Osterhaus AD
Vaccine; 2008 May; 26(21):2553-61. PubMed ID: 18430494
[TBL] [Abstract][Full Text] [Related]
4. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.
Dunham SP; Bruce J; Klein D; Flynn JN; Golder MC; MacDonald S; Jarrett O; Neil JC
Vaccine; 2006 Nov; 24(49-50):7095-108. PubMed ID: 17049683
[TBL] [Abstract][Full Text] [Related]
5. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
Lehmann R; Franchini M; Aubert A; Wolfensberger C; Cronier J; Lutz H
J Am Vet Med Assoc; 1991 Nov; 199(10):1446-52. PubMed ID: 1666101
[TBL] [Abstract][Full Text] [Related]
7. Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS.
Klonjkowski B; Klein D; Galea S; Gavard F; Monteil M; Duarte L; Fournier A; Sayon S; Górna K; Ertl R; Cordonnier N; Sonigo P; Eloit M; Richardson J
Vaccine; 2009 Feb; 27(6):928-39. PubMed ID: 19070641
[TBL] [Abstract][Full Text] [Related]
8. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
9. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.
Lockridge KM; Chien M; Dean GA; Stefano Cole K; Montelaro RC; Luciw PA; Sparger EE
Virology; 2000 Jul; 273(1):67-79. PubMed ID: 10891409
[TBL] [Abstract][Full Text] [Related]
10. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
[TBL] [Abstract][Full Text] [Related]
11. The development of a vaccine against feline immunodeficiency virus.
Hosie MJ
Br Vet J; 1994; 150(1):25-39. PubMed ID: 8025833
[TBL] [Abstract][Full Text] [Related]
12. Lessons from the cat: development of vaccines against lentiviruses.
Dunham SP
Vet Immunol Immunopathol; 2006 Jul; 112(1-2):67-77. PubMed ID: 16678276
[TBL] [Abstract][Full Text] [Related]
13. Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT.
Dean GA; LaVoy A; Burkhard MJ
Vet Immunol Immunopathol; 2004 Jul; 100(1-2):49-59. PubMed ID: 15182995
[TBL] [Abstract][Full Text] [Related]
14. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
15. [Vaccination of cats against infection with feline leukemia virus (FeLV): first recombinant vaccine and the effect of a pre-existing infection with feline immunodeficiency virus (FIV)].
Hofmann-Lehmann R; Aubert A; Wolfensberger C; Cronier J; Lutz H
Schweiz Arch Tierheilkd; 1994; 136(10):340-51. PubMed ID: 7801087
[TBL] [Abstract][Full Text] [Related]
16. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
[TBL] [Abstract][Full Text] [Related]
17. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Pu R; Coleman J; Coisman J; Sato E; Tanabe T; Arai M; Yamamoto JK
J Feline Med Surg; 2005 Feb; 7(1):65-70. PubMed ID: 15686976
[TBL] [Abstract][Full Text] [Related]
18. MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors.
Pu R; Omori M; Okada S; Rine SL; Lewis BA; Lipton E; Yamamoto JK
Cell Immunol; 1999 Nov; 198(1):30-43. PubMed ID: 10612649
[TBL] [Abstract][Full Text] [Related]
19. Vaccination against the feline immunodeficiency virus: the road not taken.
Lecollinet S; Richardson J
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):167-90. PubMed ID: 17706778
[TBL] [Abstract][Full Text] [Related]
20. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination.
Flynn JN; Keating P; Hosie MJ; Mackett M; Stephens EB; Beatty JA; Neil JC; Jarrett O
J Immunol; 1996 Oct; 157(8):3658-65. PubMed ID: 8871667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]